Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Q2 2025 Earnings Presentation
10 slides from Vitrolife Ab's earnings presentation, 2025
Slide 1: Vitrolife AB (publ) Pre-close call Q2 2025
Vitrolife AB (publ) Pre-close call Q2 2025 Bronwyn Brophy O'Connor, CEO Helena Wennerström, Acting CFO
Slide 2: Key factors to consider in Q2 2025 compared to Q2 2024
Key factors to consider in Q2 2025 compared to Q2 2024 1. Strong comparison 2. IVF Executive order 3. The Year of the Snake Exceptionally strong sales in “Within 90 days of the date of Small signs of cycle recovery in Technologies with 40% growth this order, the Assistant to the APAC but we still ha
Slide 3: 1. Strong comparable quarter for Technologies product group
1. Strong comparable quarter for Technologies product group Net sales, MSEK 215 Organic growth* Q2 2024 +40% 206 197 166 152 153 138 139 +174% +50% Americas EMEA +2% APAC Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 *in local currencies 2023 2024 2025 3
Slide 4: 2. Impact of IVF Executive Order on cycles in the US in Q2 2025
2. Impact of IVF Executive Order on cycles in the US in Q2 2025 “Within 90 days of the date of this order, the Assistant to the President for Domestic Policy shall submit to the President a list of policy recommendations on protecting IVF access and aggressively reducing out-of-pocket and health pla
Slide 5: 3. The Year of the Snake
3. The Year of the Snake • After April 17th couples undergoing IVF will not have a baby born in the Year of the Snake. • There are small signs of recovery in APAC, but we still have not seen a return to pre dragon levels. • Despite changes to reimbursement policy in China, with a shift in the site o
Slide 6: Tariff as of June 2025
Tariff as of June 2025 Current status: • US: Tariffs continue to be challenged in US courts, but they remain in force pending appeal. Some critical medical devices/components have secured temporary exclusion extensions, but most items are still subject to the 25% tariff on Chinese medical device. No
Slide 7: Currency headwinds during H1 2025
Currency headwinds during H1 2025 Currency, development H1 2025 Currency, YoY YTD 2025 Vitrolife Group’s translation exposure risk is attributable to net investments in foreign Vitrolife Group’s transaction exposure risk is attributable to income and expenses, operations. Assets and liabilities are
Slide 8: PGT-A US lawsuit update
PGT-A US lawsuit update What are the Steps Required for patients to be performed PGT-A during What is PGT-A test? their IVF Process? PGT-A is a genetic study of the embryo produced during IVF First step is Patients visiting IVF Clinic/Physician. treatment to identify numerical chromosome aneuploid
Slide 9: Reasons to invest in Vitrolife AB (publ)
Reasons to invest in Vitrolife AB (publ) • Underlying resilient market growth. • High quality brands linked with outstanding service and support. • Proven track record of profitable growth. • Innovation and technology leader within fertility. • Ambitious strategy and long-term objectives. Contact: in
Slide 10: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there